Compare Ascendis Pharma A/S (ASND) vs InMode Ltd (INMD) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

INMD trades at $15.28, up 1.8% on the day, with a bullish technical signal from moving averages and oscillators. The company reported a Q1 2026 earnings miss but maintains strong profitability with a 23.27% net income margin. Recent news includes an unsolicited acquisition proposal from Steel Partners at $16.75 per share, alongside ongoing securities fraud investigations announced in early July 2026.

The stock presents a mixed outlook; the acquisition offer and solid fundamentals suggest upside near the $16.50 consensus target, but legal scrutiny and earnings volatility pose significant risks. Investor sentiment is divided, with analysts evenly split between Buy and Hold ratings, reflecting uncertainty around the company's near-term trajectory.